{"title":"Synagis Palivizumab","description":"\u003cp\u003eDiscover our top-rated \u003cstrong\u003eSynagis (Palivizumab)\u003c\/strong\u003e for powerful RSV prevention in high-risk infants and children. Synagis is an FDA-approved monoclonal antibody that provides advanced immune protection against respiratory syncytial virus, reducing risk of severe infection and hospitalization. Trusted by pediatricians and hospitals, Synagis supports optimal lung health and immunity during RSV season. Ensure superior respiratory defense for your child with our reliable Synagis solutions.\u003c\/p\u003e","products":[{"product_id":"synagis-palivizumab-50mg-0-5-ml-single-dose-vial","title":"Synagis palivizumab 50mg\/0.5 mL Single-Dose Vial","description":"\u003cp\u003eSynagis palivizumab 50mg\/0.5 mL Single-Dose Vial is a highly effective medication used for the prevention of serious respiratory tract infections caused by the respiratory syncytial virus (RSV) in infants and children. RSV is a common virus that can lead to severe respiratory infections in young children, particularly those with weakened immune systems. Synagis palivizumab, with its active ingredient 50mg of palivizumab, is administered by injection and works by boosting the child's immunity to fight against RSV. This medication has been proven to reduce the severity and incidence of RSV infections in children, making it an essential tool in pediatric health care. Furthermore, Synagis palivizumab 50mg has been shown to significantly reduce hospitalizations and the need for intensive care in children who are at high risk of contracting RSV. With its ease of administration and minimal side effects, this medication is a crucial component in preventing serious respiratory complications in young children, making it a highly sought-after and beneficial treatment option.\u003c\/p\u003e\n\u003cp\u003eSynagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIndications:\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSynagis 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:\u003c\/li\u003e\n\u003cli\u003ewith a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season\u003c\/li\u003e\n\u003cli\u003ewith bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season\u003c\/li\u003e\n\u003cli\u003ewith hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Sobi","offers":[{"title":"Default Title","offer_id":40010860462152,"sku":"66658-0230-01","price":2495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Synagis-palivizumab-50mg-to-protect-against-RSV-infection.jpg?v=1702393826"},{"product_id":"synagis-palivizumab-100mg-1-ml-single-dose-vial","title":"Synagis palivizumab 100mg\/1 mL Single-Dose Vial","description":"\u003cp\u003eSynagis is the only FDA-approved monoclonal antibody to help protect high-risk infants against RSV.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eSynagis palivizumab 100mg\/1 mL Single-Dose Vial is a highly effective medication used to prevent serious respiratory infections in infants and young children caused by the respiratory syncytial virus (RSV). RSV is the most common cause of bronchiolitis and pneumonia in children under the age of one, making it a significant health concern for parents and healthcare providers. Synagis works by targeting the RSV virus and preventing it from replicating, therefore reducing the risk of severe lung infections. This medication has been shown to significantly reduce hospitalizations and even deaths in premature infants and children with lung or heart conditions. Its convenient single-dose vial form makes it easy to administer and its recommended dosage of once a month for a total of 5 doses during RSV season offers excellent protection. The benefits of Synagis palivizumab 100mg are clear, as it not only protects against potentially life-threatening infections, but also provides peace of mind for parents knowing their child is receiving the best prevention possible for RSV.\u003c\/p\u003e\n\u003cp\u003eSynagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIndications:\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSynagis 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:\u003c\/li\u003e\n\u003cli\u003ewith a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season\u003c\/li\u003e\n\u003cli\u003ewith bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season\u003c\/li\u003e\n\u003cli\u003ewith hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Sobi","offers":[{"title":"Default Title","offer_id":40010865836104,"sku":"66658-0231-01","price":4900.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Synagis-palivizumab-100mg.jpg?v=1698086065"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/collections\/Synagis-palivizumab-50mg-to-protect-against-RSV-infection_57b94d1b-09ad-4bcf-ab17-48b5c49169df.jpg?v=1757591410","url":"https:\/\/www.mountainside-medical.com\/collections\/synagis-palivizumab.oembed?constraint=rsv-disease","provider":"Mountainside Medical","version":"1.0","type":"link"}